TMEM97 and age-related macular degeneration: As such, developing new bioactive σ2R/TMEM97 modulators with higher selectivity for σ2R/TMEM97 may reduce the potential off-target effects, improving the potential of using non-invasive delivery routes such as systemic or topical administration for the treatment of AMD.